Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-05-25
2008-09-09
Jiang, Shaojia Anna (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S045000, C514S046000, C536S027600, C536S027620
Reexamination Certificate
active
07423144
ABSTRACT:
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
REFERENCES:
patent: 3819613 (1974-06-01), Marumoto et al.
patent: 3832341 (1974-08-01), Duschinsky
patent: 4242505 (1980-12-01), Kawahara et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5206222 (1993-04-01), Forman et al.
patent: 5219840 (1993-06-01), Gadient et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5280015 (1994-01-01), Jacobson et al.
patent: 5304277 (1994-04-01), Ohara et al.
patent: 5407793 (1995-04-01), Del Nido et al.
patent: 5443836 (1995-08-01), Downey et al.
patent: 5589467 (1996-12-01), Lau et al.
patent: 5604210 (1997-02-01), Nagaoka et al.
patent: 5789416 (1998-08-01), Lum et al.
patent: 6180615 (2001-01-01), Zablocki et al.
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6358536 (2002-03-01), Thomas
patent: 6368573 (2002-04-01), Leung
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6426337 (2002-07-01), Cox et al.
patent: 6440948 (2002-08-01), Zablocki et al.
patent: 6448236 (2002-09-01), Monaghan
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6528494 (2003-03-01), Cox et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6534486 (2003-03-01), Allen et al.
patent: 6638914 (2003-10-01), Fishman et al.
patent: 6753322 (2004-06-01), Mantell et al.
patent: 6921753 (2005-07-01), Mantell et al.
patent: 2001/0051612 (2001-12-01), Cristalli
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0055021 (2003-03-01), DeNinno et al.
patent: 2006/0034941 (2006-02-01), Dobson
patent: 2007/0238694 (2007-10-01), Salzman et al.
patent: 1164122 (1997-11-01), None
patent: 23 42 479 (1975-03-01), None
patent: 2 186 470 (1974-01-01), None
patent: 2003-0005241 (2003-01-01), None
patent: WO-94/02497 (1994-02-01), None
patent: WO-95/02604 (1995-01-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-97/33590 (1997-09-01), None
patent: WO-97/33879 (1997-09-01), None
patent: WO-98/08855 (1998-03-01), None
patent: WO-98/50047 (1998-11-01), None
patent: WO-99/20284 (1999-04-01), None
patent: WO-01/19360 (2001-03-01), None
patent: WO-01/40245 (2001-06-01), None
patent: WO-01/45715 (2001-06-01), None
patent: WO-02/055085 (2002-07-01), None
patent: WO-02/083152 (2002-10-01), None
patent: WO-03/029264 (2003-04-01), None
Muller, C.E., “Adenosine Receptor Ligands-Recent Developments part I. Agonists” (2000) vol. 7, pp. 1269-1288.
Missiaen et al., “Effect of adenine nucleotides in myo-inositol-1,4,5-triphosphate-induced calcium release” Biochemical Journal (1997) vol. 325, pp. 661-666.
Al-Mughales et al., “The chemoattractant activity of reheumatoid synovial fluid for human lymphocytes is due to multiple cytokines.”Clin. Exp. Immunol.,1996, vol. 106, pp. 230-236.
Baraldi et al., “Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynl-N6-arylcarbamoyl, andN6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1and A3Adenosine Receptor Agonists”J. Med. Chem.,1998, vol. 41, pp. 3174-3185.
Beukers et al., “New, Non-Adenosine, High-Potency Agonists for the Human Adenosine A2BReceptor with an Improved Selectivity Profile Compared to the Reference AgonistN-Ethylcarboxamidoadenosine”J. Med. Chem.,2004, vol. 47, pp. 3707-3709.
Beukers, et al., “N6-Cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a Very Selective Agonist with High Affinity for the Human Adenosine A1Receptor.”J. Med. Chem.,2003, 46:1492-1503.
Bouma et al. “Differential Regulatory Effects of Adenosine on Cytokine Release by Activated Human Monocytes.”J. Immunol.,1994, vol. 153, pp. 4159-4168.
Bradley et al., “Purine Nucleoside-Dependent Inhibition of Cellular Proliferation in 1321N1 Human Astrocytoma Cells.”J. Pharmacol. Expt. Ther.,2001, vol. 299, pp. 748-752.
Camaioni, et al., “Adenosine receptor agonists: Synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA.”Bioorg. Med. Chem.,1997, 5(12):2267-2275.
Cristalli et al., “2-Alkynyl Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists a A2Adenosine Receptors”J. Med Chem,1992, vol. 35, pp. 2363-2368.
Cristalli et al., “2-Alkynyl Derivatives of Adenosine-5'-N-ethyluronamide: Selective A2Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation.”J. Med. Chem.,1994, vol. 37, pp. 1720-1726.
Cristalli et al., “2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5'-N-ethyluronamide as Selective A2aAdenosine Receptor Agonists.”J. Med. Chem.,1995, vol. 38, pp. 1462-1472.
Dalpiaz, et al., “Synthesis and Study of 5'-Ester Prodrugs of N6-Cyclopentyladenosine, a Selective A1 Receptor Agonist.”Pharm. Res.,2001, 18(4):531-536.
De Lean, et al., “Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes.”Mol. Pharm.,1982, 21:5-16.
DeNinno et al., “3'-Aminoadenosine-5'-uronamides: Discovery of the First Highly Selective Agonist at the Human Adenosine A3Receptor”J. Med. Chem.,2003, vol. 46, pp. 353-355.
Fisher et al., “Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein”N. Engl. J. Med.,1996, vol. 334, pp. 1697-1702.
Francis et al., “Highly Selective Adenosine A2Receptor Agonists in a Series of N-Alkylated 2-Aminoadenosines”J. Med. Chem.,1991, vol. 34, pp. 2570-2579.
Hasko et al. “Adenosine Receptor Agonists Differentially Regulate IL-10, TNF-α, and Nitric Oxide Production in RAW 264.7 Macrophages and in Endotoxemic Mice,”J. Immunol.,1996, vol. 157, pp. 4634-4640.
Homma et al., “Nucleosides and Nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: A New Entry of Selective A2Adenosine Receptor Agonists with Potent Antihypertensive Activity”J. Med. Chem.,1992, vol. 35, pp. 2881-2890.
Hutchison et al., “2-(Arylalkylamino)adenosin-5'-uronamides: A New Class of Highly Selective Adenosine A2Receptor Ligands”J. Med. Chem.,1990, vol. 33, pp. 1919-1924.
Klotz et al., “Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells.”Naunyn-Schmiedeberg's Arch. Pharmacol., 1998, vol. 357, pp. 1-9.
Klotz et al., “Photoaffinity Labeling of A1-adenosine Receptors”J. Biol. Chem.,1985, vol. 260, pp. 14659-14664.
Kunkel et al.., “The role of chemokines in inflammatory joint disease”J. Leukocyte Biol.,1996, vol. 59, pp. 6-12.
Lichtenthaler, et al., “Nucleosides, XVIII1. Improved Preparation of Nucleoside 5'-Nitrates.”Synthesis,1974, 199-201.
Lohse et al., “8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)—a selective high affinity antagonist radioligand for A1adenosine receptors”Naunyn-Schmiedeberg's Arch. Pharmacol.,1987, vol. 336, pp. 204-210.
Mager et al., “Molecular simulation applied to 2-(N-alkylidenehydrazino)- and 2- (Naralkylidenehydrazino)adenosine A2agonists”Eur. J. Med. Chem.,1995, vol. 30, pp. 15-25.
Matsuda et al., “Nucleosides and Nucleotides. 103. 2- Alkynyladenosines: A Novel Class of Selective Adenosine A2Receptor Agonists with Potent Antihypertensive Effects.”J.Med. Chem.,1992, vol. 35, pp. 241-252.
McWhinney et al., “Activation of adenosine A3receptors on macrop
Jagtap Prakash
Salzman Andrew L.
Szabo Csaba
Inotek Pharmaceuticals Corporation
Jiang Shaojia Anna
Lahive & Cockfield LLP
Olson Eric S
Remillard Jane E.
LandOfFree
Purine Derivatives as adenosine A 1 receptor agonists and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine Derivatives as adenosine A 1 receptor agonists and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine Derivatives as adenosine A 1 receptor agonists and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979706